Effect of inhibition of MEK pathway on 5-aza-deoxycytidine-suppressed pancreatic cancer cell proliferation.

Pancreatic adenocarcinoma is a lethal disease because it is inoperable at the time of diagnosis. Therefore, the search for new therapeutic approaches is critical. The abnormal expression of the mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) pathway and alteration in epigenetic modification (DNA methylation and acetylation of histones) is a common feature in the majority of human pancreatic adenocarcinomas. Because DNA methyltransferase levels are regulated by the MEK pathway, we examined the effects of an MEK inhibitor, PD98059, on the action of DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-dC), the epigenetic agent in the pancreatic cell line CFPAC1. Our results showed that PD98059 significantly potentiated the capability of 5-aza-dC to induce a cessation of cell proliferation concomitant with cell cycle arrest. We also observed an increase in tumor suppressor gene expression associated with the efficacy of treatment with PD98059 and 5-aza-dC. Further studies explored the molecular mechanisms by which 5-aza-dC induced the expression of p21(WAF1). We found that 5-aza-dC induced acetylation of histone H3 on the p21(WAF1) gene promoter and demethylation status on the p21(WAF1) gene promoter region. These effects were strikingly enhanced by the concomitant blockade of the MEK pathway. Furthermore, knockdown of p21(WAF1) by small interfering RNA rescued human pancreatic cancer cells from 5-aza-dC-mediated growth inhibition. Taken together, our results show that the MEK inhibitor enhanced the effects of 5-aza-dC in human pancreatic cancer cells. These results suggest that the MEK signal pathway may be a potential target for pancreatic cancer therapy.

[1]  Seung‐Mo Hong,et al.  Unlike Pancreatic Cancer Cells Pancreatic Cancer Associated Fibroblasts Display Minimal Gene Induction after 5-Aza-2′-Deoxycytidine , 2012, PloS one.

[2]  A. Pires,et al.  Expression of growth genes in response to glycerol use in Japanese quail diets. , 2012, Genetics and molecular research : GMR.

[3]  A. Godwin,et al.  Transcriptional Regulation of hTREX84 in Human Cancer Cells , 2012, PloS one.

[4]  G. Kristiansen,et al.  The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma , 2012, Nature.

[5]  U. Bhadra,et al.  Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells , 2012, BMC Cancer.

[6]  Noriyuki Omura,et al.  Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2011, Clinical Cancer Research.

[7]  W. Stone,et al.  Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway. , 2011, Free radical biology & medicine.

[8]  P. Adams,et al.  Ras, PI3K/Akt and senescence , 2011, Small GTPases.

[9]  E. Zabarovsky,et al.  Integrin alpha9 (ITGA9) expression and epigenetic silencing in human breast tumors , 2011, Cell adhesion & migration.

[10]  C. Yeo,et al.  Subject Review: Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature , 2011, Journal of Gastrointestinal Surgery.

[11]  S. Paik,et al.  Silencing of BNIP3 results from promoter methylation by DNA methyltransferase 1 induced by the mitogen-activated protein kinase pathway , 2011, Molecules and cells.

[12]  Jide Wang,et al.  Promoter hypermethylation and histone hypoacetylation contribute to pancreatic-duodenal homeobox 1 silencing in gastric cancer. , 2010, Carcinogenesis.

[13]  J. Herman,et al.  Decreased expression and promoter methylation of the menin tumor suppressor in pancreatic ductal adenocarcinoma , 2009, Genes, chromosomes & cancer.

[14]  A. Porter,et al.  p21(WAF1) negatively regulates DNMT1 expression in mammalian cells. , 2009, Biochemical and biophysical research communications.

[15]  H. Heng,et al.  Genomic instability and histone H3 phosphorylation induction by the Ras‐mitogen activated protein kinase pathway in pancreatic cancer cells , 2009, International journal of cancer.

[16]  J. Rey,et al.  Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors. , 2009, Genetics and molecular research : GMR.

[17]  Jing-Yuan Fang,et al.  RAF may induce cell proliferation through hypermethylation of tumor suppressor gene promoter in gastric epithelial cells , 2009, Cancer science.

[18]  M. Goggins,et al.  Epigenetics and epigenetic alterations in pancreatic cancer. , 2009, International journal of clinical and experimental pathology.

[19]  G. Lomberk,et al.  The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research , 2008, Current opinion in gastroenterology.

[20]  S. Singer,et al.  Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells , 2008, Molecular Cancer Therapeutics.

[21]  R. Hruban,et al.  CpG island methylation profile of pancreatic intraepithelial neoplasia , 2008, Modern Pathology.

[22]  M. McNutt,et al.  An ATM- and Rad3-related (ATR) Signaling Pathway and a Phosphorylation-Acetylation Cascade Are Involved in Activation of p53/p21Waf1/Cip1 in Response to 5-Aza-2′-deoxycytidine Treatment* , 2008, Journal of Biological Chemistry.

[23]  高山 祐一.  MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth , 2008 .

[24]  Li Jiao,et al.  K-ras Mutation and p16 and Preproenkephalin Promoter Hypermethylation in Plasma DNA of Pancreatic Cancer Patients: In Relation to Cigarette Smoking , 2007, Pancreas.

[25]  Jong-Wook Hong,et al.  The inhibition of T-cells proliferation by mouse mesenchymal stem cells through the induction of p16INK4A-cyclin D1/cdk4 and p21waf1, p27kip1-cyclin E/cdk2 pathways. , 2007, Cellular immunology.

[26]  Li Wei Ma,et al.  p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation , 2006, Journal of cellular biochemistry.

[27]  S. Sanche,et al.  5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. , 2006, Leukemia research.

[28]  M. McMahon,et al.  Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. , 2005, Cancer research.

[29]  J. Lyssikatos,et al.  Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. , 2005, Current topics in medicinal chemistry.

[30]  A. Scarpa,et al.  Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway , 2005, Oncogene.

[31]  O. Sagol,et al.  Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics , 2005, BMC Cancer.

[32]  R. Momparler,et al.  Synergistic antineoplastic action of DNA methylation inhibitor 5‐AZA‐2′‐deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells , 2003, International journal of cancer.

[33]  Matthew Tudor,et al.  Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation , 2001, Nature Genetics.

[34]  Ling He,et al.  Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. , 2000, Cancer research.

[35]  H. Ng,et al.  Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. , 1997, Science.